|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02315 BIOCYTOGEN-B
Nominal 
15.000 -0.260 (-1.704%) Profitability Analysis
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| ROAA (%) | 1.379% | -14.591% | -23.594% | -23.571% | -18.401% |
| ROAE (%) | 4.141% | -39.640% | -50.299% | -40.404% | -29.454% |
| Return on Capital Employed (%) | 1.784% | -20.459% | -27.439% | -29.392% | -21.425% |
Margin Analysis
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Gross Profit Margin (%) | 77.670% | 70.585% | 73.378% | 69.789% | 65.864% |
| EBITDA Margin (%) | 33.419% | -12.618% | -67.152% | -110.060% | -164.321% |
| Pre-tax Profit Margin (%) | 4.380% | -53.027% | -112.638% | -153.895% | -188.013% |
| Net Profit Margin (%) | 3.421% | -53.417% | -112.749% | -153.876% | -168.844% |
Liquidity Analysis
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Current Ratio (X) | 1.526 X | 1.252 X | 1.517 X | 1.958 X | 3.494 X |
| Quick Ratio (X) | 1.519 X | 1.239 X | 1.486 X | 1.924 X | 3.470 X |
Leverage Analysis
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Total Liabilities / Total Assets(%) | 65.280% | 67.730% | 58.897% | 45.632% | 37.321% |
| Total Debt / Total Assets (%) | 23.611% | 22.214% | 14.832% | 3.900% | 3.478% |
| Net Debt / Total Assets (%) | 6.890% | 5.899% | -6.986% | -16.356% | -28.761% |
| Total Debt / Shareholders' Funds (%) | 68.374% | 69.235% | 36.229% | 7.200% | 5.567% |
| Long Term Debt / Shareholders' Funds (%) | 41.278% | 43.379% | 21.258% | 5.043% | 4.597% |
| Net Debt / Shareholders' Funds (%) | 19.954% | 18.387% | -17.064% | -30.199% | -46.038% |
| Net Cash / (Debt) ($) | (166.427M) | (144.502M) | 195.602M | 376.646M | 669.126M |
| Net Cash / (Debt) per share ($) | (0.417) | (0.362) | 0.490 | -- | -- |
| Total Debt / Capital Employed (%) | 30.327% | 29.069% | 18.930% | 4.838% | 4.050% |
| Interest Coverage Ratio (X) | 1.468 X | N/A | N/A | N/A | N/A |
Efficiency Analysis
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Inventory Turnover (Day) | 9.424 Day | 22.518 Day | 43.328 Day | 39.391 Day | 33.654 Day |
| Receivables Turnover (Day) | 69.242 Day | 63.658 Day | 72.049 Day | 87.666 Day | 96.779 Day |
| Payables Turnover (Day) | 54.113 Day | 81.823 Day | 84.991 Day | 97.819 Day | 126.108 Day |
| Remarks: | Real time quote last updated: 28/03/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB 33,542,000 |
| %Change | -- |
| EPS / (LPS) | RMB 0.080 |
| NBV Per Share (¥) | RMB 2.088 |